Lead Product(s) : Dubermatinib,Decitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study aims to determine the safety and maximum tolerated dose of dubermatinib in combination with decitabine and evaluate the composite complete response rate.
Brand Name : TP-0903
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 23, 2020
Lead Product(s) : Dubermatinib,Decitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dubermatinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary findings from the Phase 1a/b first-in-human study indicated dubermatinib was well tolerated with a manageable safety profile as a monotherapy or in combination with immunotherapy or tyrosine kinase inhibitor (TKI).
Brand Name : TP-0903
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2020
Lead Product(s) : Dubermatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dubermatinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tolero's investigational agent, dubermatinib (TP-0903), an AXL receptor tyrosine kinase (RTK) inhibitor has been selected for a new arm in the trial for patients with TP53 mutations and/or complex karyotype.
Brand Name : TP-0903
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2020
Lead Product(s) : Dubermatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?